TNXP News and Press, Tonix Pharmaceuticals Holding Corp. From 12/29/25

2025-12-29 11:15:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) provided program updates on TNX-4800, a long-acting human monoclonal antibody designed for seasonal prophylaxis against Lyme disease, which targets the outer surface protein A of Borrelia burgdorferi , the bacterium that ca...

2025-12-29 11:09:38 ET Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has entered into a securities purchase agreement with Point72 for a registered direct offering of 615,025 shares of common stock at $16.26 per share, or pre-funded warrants to purchase up to an aggregate of 615,025...

2025-12-29 08:02:00 ET More on Tonix Pharmaceuticals Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook Tonix: Assessing Tonmya's Commercial Potential Ahead Of Q4 2025 Launch Tonix ...

CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72 f...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product  of TNX-4800 (anti-Borrelia OspA mAb) available for clinical trials in early 2027 Approximately 70 million p...

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies CHATHAM, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceutica...

2025-12-09 13:30:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated commercial-stage biotechnology company, appointed Irina Ishak as General Counsel effective Dec. 8, 2025. Ishak, a longtime advisor to Tonix, will lead the Company’s legal, corporate governance and co...

CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective Decemb...

2025-12-04 09:05:00 ET BioMedWire Editorial Coverage : Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide ...

2025-11-24 15:35:46 ET The last time I wrote an article on Tonix Pharmaceuticals Holding Corp. ( TNXP ), it was in a Seeking Alpha article entitled "Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years." With respect to this article, I noted...